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Phospholipase A2 enzymes: structural diversity in lipid
messenger metabolism
A Dessen
The phospholipases A2 (PLA2s) are a large family of
enzymes with varied lipidic products which are involved
in numerous signal transduction pathways. The structural
and functional characterization of several PLA2s have
revealed the various mechanisms used by these
enzymes to ingeniously manipulate the phospholipidic
metabolic machinery.
Address: European Molecular Biology Laboratory, 6 rue Jules
Horowitz, 38000 Grenoble, France.
E-mail: dessen@embl-grenoble.fr 
Structure 2000, 8:R15–R22
0969-2126/00/$ – see front matter 
© 2000 Elsevier Science Ltd. All rights reserved.
Introduction
The importance of lipid messengers is reflected in their
involvement in fundamental, highly regulated cellular
processes, such as growth, adhesion, secretion and apop-
tosis, and medical concerns ranging from thrombosis to
asthma [1]. Of particular interest are the eicosanoids,
20-carbon fatty acids that include the cyclooxygenase-
derived leukotrienes and the lipooxygenase-generated
prostaglandins, both powerful mediators of inflammation
[2]. It is therefore of no surprise that much attention has
been given to the common element of all lipid messen-
ger pathways: the phospholipases that are essential to
their biosynthesis.
The characterization of the molecular details of phospho-
lipase biochemistry has been challenging for several
reasons. Phospholipases that are involved in signaling
pathways are typically present in low amounts in cells,
often displaying low solubility, and their hydrophobic sub-
strates are preferred in aggregated form. These facts alone
are enough to complicate assays and their analyses, and
yet phospholipases have been known since the 1950’s
when their activity was first discovered in pancreatic juice
and cobra venom [3,4]. Since then, elegant efforts in
cloning, expression, purification, sequencing, and struc-
ture determination, as well as studies of regulation and
localization have helped to uncover details of many phos-
pholipase groups [5]. 
Within the phospholipases, by far the most complex and
well-known element is the phospholipase A2 superfamily.
Phospholipase A2 enzymes (PLA2s) catalyze the hydrolysis
of the sn-2 bond of phospholipids, generating free fatty
acids and lysophospholipids, and are thus key enzymes
which control the release of lipid mediator precursors. The
diversity within the enzyme family can be classified
according to localization of the individual member
(secreted versus cytosolic), sequence homology, cation
requirement and molecular weight, generating at least
nine major groups with varied molecular characteristics [5].
But what is the need for such diversity? The answer lies in
the fact that mammalian tissues and cells, which often
contain more that one PLA2, possess differently regulated
pathways for fatty acid metabolism, requiring PLA2s to
play crucial roles in cellular responses as diverse as phos-
pholipid digestion and turnover, membrane remodeling,
host defense, signal transduction and the production of
inflammatory mediators [4]. The divergence displayed by
PLA2s in terms of structure, cation requirement and cat-
alytic mechanism is remarkable when considering that
they all target phospholipidic substrates and catalyze an
acyl hydrolysis reaction. This review will concentrate on
the structural aspects of this important family of enzymes,
with particular emphasis on the recent crystal structure of
cytosolic PLA2. The new and unexpected fold of cystolic
PLA2 reveals novel eccentricities employed by such
enzymes in the manipulation of fatty acid metabolism.
Structure and mechanism of secreted PLA2 enzymes
Secreted PLA2s (sPLA2s) are the most well-studied
members of the PLA2 family and possibly of all lipid-
metabolizing enzymes. Primarily on the basis of amino
acid sequence and disulfide positioning, sPLA2s have
been classified into three major types (I, II and III) and
two different subtypes (A and B). They have been iso-
lated from various snake and bee venoms, as well as from
several mammalian sources [4]. The functions performed
by sPLA2s range from the digestion of dietary fat, to cell
proliferation and migration. In particular, the abundance
of group IIA sPLA2 in various inflamed tissues, including
the plasma of patients with sceptic shock and rheumatoid
arthritis, suggests that it may have a crucial role in the
pathogenesis of inflammation. Venom sPLA2s, on the
other hand, seem to be directly involved in prey digestion;
in addition, they have been reported to have roles in
neurotoxic, myotoxic and anticoagulatory processes [6]. 
The sPLA2s are cysteine-rich molecules that catalyze the
cleavage of the 2-acyl ester bond of phospholipids without
any fatty acid selectivity and in a Ca2+-dependent manner.
Disulfide bridges ranging in number from five to eight [5]
guarantee a rigid three-dimensional structure, as well as sta-
bility and proteolytic resistance, features that ensure
sPLA2s their full activity in the extracellular fluids where
they are found [7]. X-ray crystal structures of sPLA2s from
different sources [8–14] have revealed a common fold with
st8211.qxd  02/29/2000  12:18  Page R15
three major α-helical segments, a double-stranded antipar-
allel β sheet (the β wing), and a highly evolutionarily con-
served Ca2+-binding loop; diversions from commonality
include a small, surface-exposed segment observed only in
type I sPLA2s (the ‘elapid’ or ‘pancreatic’ loop; blue in
Figure 1a) and a six amino acid C-terminal extension which
characterizes type II sPLA2s. The active site of sPLA2s is
located at the bottom of a channel lined with hydrophobic
residues and is composed of a highly conserved His–Asp
catalytic dyad and a tightly bound, heptacoordinated Ca2+
atom (Figure 2a). Crystal structures of sPLA2s in complex
with inhibitors or transition-state analogs have shown the
alkane chains of such molecules to lie roughly parallel in
the channel, extending between 9 and 14 Å from the cat-
alytic histidine towards the opening of the channel near the
N-terminal helix [10–14]. In the absence of a catalytic triad,
as observed in serine proteases, sPLA2s are incapable of
hydrolyzing the 2-acyl group of diacylphospholipids
through an acyl–enzyme intermediate; instead, the catalytic
histidine, aided by a neighboring aspartate residue, polar-
izes a nearby water molecule, which then attacks the sub-
strate sn-2 bond. The Ca2+ atom actively participates in
catalysis by stabilizing the resulting transition state, and
reassumes a state of heptacoordination as two water mol-
ecules move into the active site upon collapse of the tetra-
hedral intermediate and product release [15]. 
Based initially on observations that not all catalytically
active venom sPLA2s are toxic and several catalytically
inactive sPLA2s show myotoxic characteristics, it has now
been shown that particular sPLA2s possess high-affinity
cellular receptors (N-type and M-type) the recognition of
which elicits toxic responses. Initially identified in brain
tissue, N-type receptors are selectively recognized by neu-
rotoxic sPLA2s. Although their molecular structure and
physiological roles are still unclear, it is known that recog-
nition occurs mostly through elements of the sPLA2
hydrophobic channel and Ca2+-binding loop [16]. Con-
versely, M-type receptors, which recognize different non-
neurotoxic sPLA2s, have been well characterized as type I
transmembrane molecules with a cysteine-rich N-terminal
domain, a fibronectin type II unit, and eight repeats of a
carbohydrate-recognition domain (CRD) followed by a
single transmembrane region and a short cytoplasmic tail
[17]. Site-directed mutagenesis and systematic CRD dele-
tion studies of mammalian M-type receptors indicate that
neither the cysteine-rich nor the fibronectin-like type II
domains are involved in sPLA2 recognition, but it is
CRD5 that provides the majority of binding contacts [18],
although there are no carbohydrate chains on the sPLA2s.
Structural elements of the sPLA2s involved in M-type
receptor interactions lie within or close to the
Ca2+-binding loop; however, the presence of Ca2+, which
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Figure 1
A gallery of lipase folds. (a) sPLA2. The
compact 14 kDa molecule harbors an elapid
loop (blue) and a tightly bound Ca2+ ion (pink)
located near the active-site His—Asp dyad.
(b) cPLA2. The C2 domain is in purple, with
two tightly bound Ca2+ atoms in red. The
catalytic domain is composed of a central
β sheet (yellow) and a cap region (pink),
which harbors a highly flexible lid that covers
the active-site dyad. Notice the lack of
interdomain contacts between the C2 and
catalytic units. (c) Phospholipase Cδ1 has a
vast area of contact between its C2 domain
(purple) and catalytic domain (yellow). The
EF-hand domain (red) is behind the C2
domain. (d) Cutinase. The smallest
α/β hydrolase contains a solvent-exposed
active site and thus does not undergo
interfacial activation. The catalytic serine is
depicted on the nucleophilic elbow.
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is essential for enzymatic activity, does not seem to be
required for receptor binding [19]. The identification of
N- and M-type receptors provided the first definitive evi-
dence that sPLA2s possess functions that are independent
of their enzymatic activity [17].
The cytosolic enzymes: Ca2+-independent PLA2s
In most tissues, the synthesis of eicosanoidal inflammatory
mediators such as leukotrienes and prostaglandins is
limited by the availability of their common precursor, free
arachidonic acid, which must be hydrolyzed from phos-
pholipidic membranes [20]. Leukotrienes have a role in
the pathophysiology of asthma by inducing airflow
obstruction through bronchoconstriction, increased secre-
tion of mucus, and migration of inflammatory cells into air
passages of asthmatic patients. Prostaglandins are media-
tors of both asthmatic and arthritic processes [21]. Hence,
the control of the level of free arachidonic acid in cells
must require a highly regulated mechanism.
Although Ca2+-independent PLA2s (iPLA2s) do not
seem to actively participate in the stimulation of arachi-
donic acid release from membranes due to their general
lack of specificity for arachidonate-containing substrates,
they establish their mark in arachidonic acid metabolism
by playing an important role in phospholipid fatty acid
remodeling [22]. The deacylation/reacylation cycle of
membrane phospholipids, known as the Lands cycle,
involves the cleavage of phospholipids by an intracellu-
lar phospholipase to generate a 2-lysophospholipid,
which can subsequently be reacylated with a different
fatty acid. The key element of this cycle is the PLA2
which generates the 2-lysophospholipid used in the acy-
lation reaction. That is where the iPLA2s step in — by
providing the lysophospholipid acceptor, they partici-
pate in the regulation of incorporation of arachidonic
acid and other unsaturated fatty acids into membrane
phospholipid [6,22]. 
To date, few intracellular iPLA2s (type VI) have been
purified to homogeneity, and such enzymes have proven
recalcitrant to detailed biochemical analysis because of
their lability, low specific activities, and low abundance in
cells. Hence, a detailed structural and mechanistic
description will have to await further studies. However,
efforts in cloning and purification have identified iPLA2s
with diverse biochemical characteristics, ranging in mol-
ecular weight from 38 kDa to 85 kDa and being capable of
forming 250–400 kDa oligomeric complexes [6]. Notably,
the iPLA2s from Chinese hamster ovary (CHO) cells and
P388D1 macrophage-like cells contain a lipase motif
(Gly-X-Ser-X-Gly) displaying a putative active-site serine,
as well as eight ankyrin repeats that have not been identi-
fied in any other PLA2; the repeats were suggested to
function in the ordered association of the subunits to give
the oligomeric complex [23,24].
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Figure 2
Distinct active sites for acyl hydrolysis. Catalytic residues are
highlighted in green. (a) The sPLA2 active site consists of a His–Asp
pair and a heptacoordinated Ca2+ atom the function of which is to
stabilize the reaction transition state. Other residues that also contact
inhibitor molecules in co-complex structures are shown. (b) The active
site of a neutral lipase (PDB code 1ETH) contains a classic
His–Asp–Ser triad reminiscent of that of serine proteases. The
oxyanion hole region is shown in yellow, as in (c). Other residues
relevant for inhibitor molecule contact are also displayed. (c) The active
site of cPLA2 lacks histidine and therefore differs from that of a classic
lipase. Ser228 is located on the nucleophilic elbow. The sidechain of
Arg200 may stabilize the phosphoryl moiety of a bound substrate.
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Little is known about the catalytic mechanism of iPLA2s,
except for the obvious lack of Ca2+ requirement and their
selective inhibition by bromoenol lactone (BEL), a mech-
anism-based molecule originally proposed as a serine pro-
tease inhibitor [25]. The presence of a serine residue in a
classic lipase motif together with the results of studies
with BEL point to the possible employment of a
serine–acyl intermediate in iPLA2 catalysis. 
Cytosolic phospholipase A2: membrane association and
activation by Ca2+
Of all members of the vast PLA2 family, it is the cytosolic
PLA2 (cPLA2 or type IV PLA2) which has the most impor-
tant role in lipid messenger biosynthesis. Although three
isozymes of this group have been identified so far (α, β
and γ) [26–28], it is cPLA2-α which is the best character-
ized and the most relevant for intracellular signaling (and
will thus be referred to henceforth simply as cPLA2). 
cPLA2 is highly selective for phospholipidic substrates
with arachidonic acid at the sn-2 position [26,29] and thus
has a crucial role in eicosanoid biosynthesis. Interestingly,
the cyclooxygenases (COX-1 and COX-2) which catalyze
the metabolism of arachidonic acid to prostaglandins are
localized in the nuclear membrane, while the leukotriene
biosynthesizing enzyme 5-lipoxygenase translocates from
the cytosol to the perinuclear membrane in response to an
increase in intracellular Ca2+ [30], as does cPLA2 [31,32].
This chain of events is verified by the observation that
activation or increased expression of cPLA2 is linked to
increased arachidonate release as well as leukotriene and
prostaglandin synthesis [33,34]. The most remarkable evi-
dence regarding the strategic importance of cPLA2 in
eicosanoid biosynthesis, however, comes from analyses of
cPLA2 knockout mice, whose peritoneal macrophages are
incapable of generating leukotrienes, prostaglandins or
PAF [35,36]. The relevance of the role of these three mes-
sengers in the pathophysiology of different inflammatory
processes, coupled to the high specificity of cPLA2 for
arachidonate phospholipids, makes cPLA2 an attractive
target for drug discovery — its specific inhibition would
simultaneously block the biosynthetic pathways of all
three molecules.
cPLA2 is an 85 kDa molecule composed of an N-terminal
C2 domain (138 amino acids; purple in Figure 1b) and a
catalytic unit with 611 residues (yellow and pink
Figure 1b [37]). Maximal activation of cPLA2 in intact
cells requires mitogen-activated protein (MAP) kinase
directed phosphorylation [34,38]; this event on its own,
however, is insufficient for such activation if it occurs in
the absence of an increase in intracellular Ca2+ concentra-
tion, a requirement for C2-mediated translocation of
cPLA2 to the target membrane [26,31,32,37]. The C2
domain of cPLA2, like its structural counterparts observed
in signal-transduction and vesicle-fusion proteins such as
protein kinase C, GTPase-activating protein, synaptotag-
min and phospholipase Cδ1, has been shown to bind
phospholipid membranes in a Ca2+-dependent manner. A
clear ubiquitous role for C2 domains in bilayer targeting is
also supported by the observation that various compo-
nents of cellular membranes, such as phospholipids, inosi-
tol phosphates and other membrane-associated proteins,
have been identified as potential ligands [39].
C2 domains consist of an eight-stranded antiparallel
β sandwich which in many cases coordinates between one
and three Ca2+ atoms through a constellation of acidic
residues on three Ca2+-binding loops (CBLs or ‘jaws’)
[40–43]. Membrane binding is accomplished mostly by
residues located on and around the apex of the CBL
region. In the C2 domain of cPLA2, these amino acids
have been implicated in interface recognition through the
employment of methods ranging from the detection 
of N15/NH heteronuclear single-quantum coherence
(HSQC) shifts upon incubation of C2 with dodecylphos-
phocholine micelles [43] to cysteine engineering followed
by fluorescence probing [39]. It is conceivable that when
phospholipids bind to the C2 domain they fill unsatisfied
coordination sites on the bound Ca2+ ions [44], which
explains why cPLA2 binding to phosphatidylcholine vesi-
cles is enhanced tenfold in the presence of Ca2+ [45].
Thus, for cPLA2, upon a submicromolar increase in intra-
cellular Ca2+ concentration, the C2 domain recruits the
Ca2+-independent catalytic domain to the nuclear or endo-
plasmic reticulum (ER) membranes, presenting it to its
substrate [26,37,39]. The function of the C2 domain in
cPLA2 biochemistry is thus clear: it must tether the full-
length molecule to the membrane, but must do so in a way
as to present the catalytic domain to its substrate in a pro-
ductive fashion. Hence, the relative interdomain orienta-
tion is of key importance for cPLA2 activity. This is also
the case for inositol-specific phospholipase Cδ1 (PCLδ1;
Figure 1c), which catalyzes the hydrolysis of membrane-
bound phosphatidyl inositol-4-5-bisphosphate into two
second messengers, namely D-myo-inositol-1,4,5-triphos-
phate and sn-1,2-diacylglycerol, in response to diverse
extracellular signals. PLCδ1 is a tetradomain molecule; in
addition to the C2 and catalytic units, it contains an EF
hand and a pleckstrin homology (PH) domain. Based on
crystallographic evidence, the mode of PLCδ1 binding to
the membrane involves the initial tethering of the mol-
ecule through the PH domain, whereas the function of C2
is to fix the catalytic unit, and hence the active site, in
close apposition to the substrate interface [40,41]. 
A comparison of the surface diagrams of full-length cPLA2
[46] and PLCδ1 [40,41] through a superposition of their
C2 domains allows visualization of the critical function of
C2 in orienting the catalytic domains with respect to the
target membrane. In Figure 3, the CBL region of both C2
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domains (superimposed) points towards and interacts with
the interface. It is clear that the C2 domains of cPLA2 and
PCLδ1 place the active sites in approximately the same
orientation. Interestingly, the vast hydrophobic contact
surface between the C2 and catalytic domains of PLCδ1
does not allow further interdomain rotation, suggesting
that this orientation is optimal for membrane interaction.
Similarly, the relative orientation of the cPLA2 domains
allows C2 to fulfill its function of tethering cPLA2 to the
membrane, juxtaposing the active-site region and the sub-
strate interface. In addition, due to the lack of major con-
tacts between the cPLA2 C2 and catalytic units (see
Figure 1b), an additional small interdomain rotation could
be possible. The orientation of the cPLA2 domains
observed in the crystal structure is biochemically produc-
tive, and is clearly an essential element of the enzyme’s
cellular function. 
The catalytic domain of cPLA2: an original fold for a new
enzymatic mechanism
The structure determination of multiple lipases have
revealed that they all share a common topological feature,
namely the α/β hydrolase fold, which consists primarily of
a central, mostly parallel β sheet interwoven by α helices
[47,48]. This α/β structure encompasses a single domain
which can range from 197 residues (Fusarium solani
cutinase; Figure 1d) to 582 amino acids (mouse acetyl-
cholinesterase), indicating that variations within the fold
are generated by the addition of secondary structure units
without the inclusion of new domains [49]. The central
β sheet has a left-handed superhelical twist, forcing the
first and last strands to cross at an approximate angle of
90° to one another. Although the positions of the
β strands are conserved, the twist of the β sheet varies
among the different enzymes, as do the orientations of
the α helices [48].  
In addition to the common fold, lipases possess a serine-
acid-histidine catalytic triad reminiscent of the serine pro-
teases (Figure 2b) and proceed catalytically through a
serine–acyl intermediate. Within the twisted β sheet, the
nucleophilic serine is located on the ‘nucleophilic elbow’,
a tight turn between a central α helix and its preceding
β strand [47,48]. The commonality of the α/β hydrolase
fold, including identical positioning of the catalytic
residues (both in terms of sequence and three-dimen-
sional localization) [48] reveal a framework that seems to
have diverged from a common ancestor, generating
enzymes which differ in their substrate-binding sites but
preserve the arrangement of the catalytic triad [47].
Prior to structure solution, cPLA2 showed signs that it too
could be a member of the α/β hydrolases. Its mechanism
proceeds through a serine–acyl intermediate [50,51]; the
nucleophile, identified as Ser228 by site-specific mutagen-
esis, is located in the Gly-Leu-Ser-Gly-Ser sequence,
which is highly reminiscent of the classic Gly-X-Ser-X-Gly
lipase motif [52]. In addition to Ser228, Asp549 and Arg200
were also shown to be essential for cPLA2 activity, but
none of the 19 histidine residues were shown to have any
catalytic role [53]. This fact suggested that the catalytic
domain of cPLA2 might hold structural surprises. 
The X-ray crystal structure of cPLA2 [46] indeed reveals a
catalytic domain harboring a twisted central β sheet
(Figure 1b), with Ser228 located on a ‘nucleophilic elbow’.
Beyond these two elements, however, there are no further
similarities with α/β hydrolases. After the formation of the
initial part of the β sheet, the amino acid chain is detracted
from the core to form a highly basic, 180-residue region
which positions itself between the active site (partly cover-
ing it) and the C2 domain — the ‘cap’ (residues 370–548;
pink in Figure 1b). The cap is composed of two sets of
antiparallel β strands and four α helices, a fold which pos-
sesses no similarity to any known structure. Although the
specific function of the cPLA2 cap is unknown, its large
number of solvent-exposed, basic amino acids (the ‘basic
patch’) as well as its strategic location, facing the proposed
membrane-binding region, are of note (see Figure 3).
Because cPLA2 has affinity for anionic phospholipids
[45,54], it is tempting to propose that this charged region
in cPLA2 has a role in contacting such acidic substrates
[46]. Interestingly, other membrane-targeting enzymes
that also reveal a striking preference for negatively charged
substrates, such as type IIb phosphatidylinositol phos-
phate kinase [55], several sPLA2s [56], protein kinase Cδ
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Figure 3
Superposition of surface diagrams of cPLA2 (yellow) and phospholipase
Cδ1 (white) through their C2 domains. Residues in C2 that have been
shown to bind lipids in N15/NH HSQC experiments (concentrated
around the CBL region) [43] are depicted in dark blue. Active sites of
both molecules (red) are similarly positioned and strategically oriented to
interact with the target membrane. In cPLA2, the basic patch region is
also available for bilayer contact. A flexible lid (pink) covers the active-
site funnel and must move to allow substrate access. 
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[57] and PLCδ1 itself [40], also possess basic surface
regions. A basic patch observed in the trimeric matrix
protein of both human immunodeficiency virus 1 and
Simian immunodeficiency virus 1 has also been implicated
in stabilization of the molecule on the internal side of the
acidic viral membrane [58,59]; these observations suggest a
ubiquitous interface-association role for such charged
regions on membrane-binding proteins. 
In addition to contacting the membrane interface, the
multifunctional cap region of cPLA2 also harbors a flexible
lid which, in the crystal structure, covers the buried active
site (pink in Figure 3). Analysis of this active site reveals
yet another difference between cPLA2 and enzymes of
the α/β hydrolase family: the lack of any histidines in a
10Å radius around the nucleophilic Ser228 (Figure 2c).
Since mutagenesis studies failed to identify any histidine
residue that could act in a classic catalytic triad as seen in
serine proteases [46], this is not completely surprising. It is
of note, however, that the active site of cPLA2 lacks any
sidechains that could replace the histidine residue identi-
fied in all α/β hydrolases to date [53]. Even Arg200, the
relevance of which in catalysis was highlighted by the lack
of activity in a Arg200→Lys mutant [53], positions its
guanidinium group 9 Å away from the Oγ atom of Ser228,
and is thus not a candidate. These observations led to the
proposal of a catalytic mechanism for cPLA2 which obvi-
ates the participation of a histidine residue [46]. In this
model, Arg200 has a role in stabilizing the phosphoryl
moiety of an incoming phospholipidic substrate. Ser228,
activated by Asp549, attacks the sn-2 ester of a bound sub-
strate molecule. The oxyanion hole, formed by the back-
bone atoms of Gly197 and Gly198 (located on the yellow
turn in Figure 2c), polarizes the ester and stabilizes the
transition state of the developing tetrahedral intermediate.
Hydrolysis of the formed serine–acyl intermediate is then
promoted by a bound water molecule, leaving cPLA2 free
to bind another phospholipid substrate and ready to repeat
the cycle.
Conformational change and interfacial activation
By far the most fascinating phenomenon associated with
lipid metabolism and lipase structure is that of ‘interfacial
activation’, which describes the dramatic increase in lipase
activity when substrate levels exceed the critical micellar
concentration (CMC) [60]. Although distinct in structure
and catalytic mechanism, sPLA2s, cPLA2, and various
lipases of the α/β hydrolase family all undergo interfacial
activation. Studies into the molecular basis of interfacial
activation of lipases have resulted in the formulation of
two main theories. The ‘substrate hypothesis’ suggests
that factors such as concentration gradient and pressure at
the membrane surface have important roles in the genera-
tion of this phenomenon. Conversely, the ‘enzyme
hypothesis’ suggests that lipases undergo localized confor-
mational changes upon membrane interaction. It is now
apparent that both the nature of the substrate as well as
conformational changes in the protein may contribute to
enzymatic activation at the interface [61].
X-ray crystallographic studies of secreted PLA2s, both in
apo form and complexed to inhibitors, suggest rigid
enzymes in which no conformational changes can occur
upon interaction with the lipid–water interface. These
studies, in conjunction with other biochemical evidence,
suggest that catalysis at the interface occurs as a result of
facilitated substrate diffusion from the binding surface
through a hydrophobic channel that leads to the sPLA2
active site [15]. Recently, electron paramagnetic reso-
nance (EPR) based membrane-docking methods have
shown that the surface region of sPLA2s which surrounds
the opening of the hydrophobic channel in fact constitutes
the interfacial binding surface (i-face) [62]. The i-face par-
ticipates in juxtaposition between enzyme and membrane
(obviating membrane penetration) so that phospholipid
transfer may occur without solvation of the hydrophobic
alkyl groups [15,56] and in the absence of conformational
changes. Notably, elegant charge-reversal mutagenesis
studies have identified a patch of basic residues located on
the i-face that has an important role in anionic phospho-
lipid recognition and interfacial binding [63].
The explanation for the activation phenomenon of neutral
lipases, however, has had a different history. Crystal struc-
tures of several lipases of the α/β hydrolase family have
revealed active sites occluded by surface loops (or ‘lids’),
which must undergo a conformational change in order for
catalytic residues to be exposed to the substrate. Notably,
lid movement also exposes vast hydrophobic areas which
surround the site itself, and are thus likely to be stabilized
by a lipidic interface. In several cases, this conformational
change is necessary to strategically localize the oxyanion
hole within the active-site region. The crucial role played
in interfacial activation by structural elements of the
lipases themselves is also clear in the crystal structure of
cutinase, a small lipase which contains a solvent-exposed
active site and thus does not undergo interfacial activation
[64] (Figure 1d).
cPLA2 also undergoes the phenomenon of interfacial acti-
vation by displaying a 1500-fold higher specific activity in
the presence of micellar substrate [37]. Again, a structural
explanation for this effect can be elicited. The crystal struc-
ture of human cPLA2 [46] shows that an amphipathic lid
covers the active site of the enzyme; short flexible regions
are ideally positioned to serve as hinges for the moveable
lid (see Figure 3). An open cPLA2 lid would reveal a 30 Å
wide hydrophobic platform funneling down into a deep
active site, with members of the catalytic dyad located at
the bottom of a 7 Å funnel stalk. The surface of the funnel
should provide an optimal binding cradle for fatty acyl ele-
ments of the target interface, certainly a stabilizing factor of
R20 Structure 2000, Vol 8 No 2
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major importance for cPLA2 activation. The location of the
Ser228–Asp549 dyad partway into the body of the catalytic
domain of cPLA2 also suggests that, in order for the sub-
strate to come into contact with the active site, it is neces-
sary for cPLA2 to become imbedded in the membrane
itself. This hypothesis is supported by the existence of a
7 Å hydrophobic rim protruding from the base of the
active-site funnel, which could be involved in interface
recognition, as well by the observation that cPLA2 activity
is inhibited in the presence of sphingomyelin-rich mem-
branes [54]. It is of interest that PLCδ1, which also displays
a hydrophobic rim around the active site and the interface-
recognition mechanism of which has been hypothesized to
involve partial insertion of the catalytic domain into the
membrane [40], is also inhibited by sphingomyelin [65].
Sphingomyelin has been reported to decrease membrane
hydration through an increase in interlipid hydrogen
bonding, causing the interface to become more rigid; this
could inhibit protein penetration, and in the case of cPLA2,
hinder access of substrate into the deep active site [46].
Conclusions
PLA2 enzymes owe the great interest they have generated
over the past decades to their key activities in lipid media-
tor biosynthesis. Eicosanoids, powerful inflammatory sig-
naling molecules, metabolically depend on the release of
arachidonic acid from phospholipidic membranes by
PLA2s, ensuring that these enzymes are under tight regu-
latory control and thus making them fascinating targets for
biochemical studies. Due to their low abundance in cells
and preference for substrates in aggregated forms,
however, PLA2s have been difficult to characterize; in
addition, the high molecular weight PLA2s have provided
crystallographic challenges. 
The relationship between the structural diversity of the
PLA2 family and the cellular processes in which their
diverse lipid messenger products are involved is finally
coming into perspective. Low molecular weight sPLA2s
target phospholipidic substrates without fatty acid selec-
tivity and have biological functions that reflect either their
catalytic activities or interactions with specific receptors;
their compact three-dimensional structures reveal a
framework that must be sealed onto its bilayer-
sequestered substrate, allowing it to diffuse into a deep
hydrophobic catalytic channel. On the other hand, cPLA2
is the most specific enzyme targeting arachidonyl phos-
pholipids, and does so by employing its C2 domain in an
initial tethering step which positions the catalytic unit
appropriately for partial membrane embedding, lid
opening and active-site access by the substrate. The
essential nature of PLA2s for the generation of lipidic
messengers holds the key to the most exciting use for the
knowledge gained in their structural and functional analy-
sis: the design of novel, specific metabolic inhibitors for
the control of a wide range of cellular processes. 
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